Following its previous announcement that it planned to acquire all of the outstanding stock of Pioneer for $130 million in cash, RTI Biologics has announced that it has completed its acquisition of the company.
According to a press release, the transaction was funded through a combination of cash on hand, a five-year $80 million senior secured credit facility, which includes a $60 million term loan and a $20 million revolving credit facility, from TD Bank, TD Securities USA LLC, and Regions Bank, and a $50 million concurrent private placement of convertible preferred equity from Water Street Healthcare Partners (Water Street), a strategic private equity firm focused exclusively on the healthcare industry.
The press release reported that, effective immediately, the new name of the company is RTI Surgical. The company’s worldwide headquarters will remain in Alachua, USA, and the stock will continue to trade on the Nasdaq Global Market under the symbol RTIX.
As part of the transaction, RTI has appointed two representatives from Water Street to serve on its board of directors. Curt Selquist, an operating partner with more than 35 years of healthcare experience, will serve as a director. Prior to Water Street, Selquist was company group chairman of Johnson & Johnson Medical and Johnson & Johnson Healthcare Systems. Joining Selquist on the board is Ned Villers, a partner with Water Street who has invested in companies specialising in medical products and healthcare services since 1999.
“The acquisition of Pioneer supports RTI’s strategic initiatives to expand our current implant portfolio into metals and synthetics, grow direct distribution and increase our global footprint,” said Brian K Hutchison, president and chief executive officer of RTI Surgical. “RTI Surgical is now positioned for growth as a global surgical implant company providing orthopaedic and biologic implant solutions for surgeons and patients around the world. We are excited about the many opportunities this acquisition brings to the company.”